Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial
- Gibson, B.E.
- Webb, D.K.
- Howman, A.J.
- Graaf, S.S. de
- Harrison, C.J.
- Wheatley, K.
DOIAbstract
Item does not contain fulltextThe Medical Research Council Acute Myeloid Leukaemia 12 (MRC AML12) trial (children) addressed the optimal anthracenedione/anthracycline in induction and the optimal number of courses of consolidation chemotherapy. 504 children (<16 years) with AML were randomized between mitoxantrone/cytarabine/etoposide or daunorubicin/cytarabine/etoposide as induction chemotherapy and 270 entered a second randomization between a total of four or five courses of treatment. Ten-year event-free (EFS) and overall survival (OS) was 54% and 63% respectively; the relapse rate was 35%. There was no difference in complete remission rate between the induction regimens, but there was a benefit for mitoxantrone with regard to relapse ra...
Add to ORKG